Vanderbilt Medical Center Initiates Plavix PGx Testing for All Cardiac Catheterization Patients | GenomeWeb

By Turna Ray

Vanderbilt University Medical Center has launched a pharmacogenomics program in which all heart disease patients who undergo cardiac catheterization at its medical center — approximately 4,000 patients per year — will receive genetic testing to determine their response to the antiplatelet drug Plavix.

Additionally, in an effort to integrate the use of genomic data into clinical care, the university will incorporate these patients' genetic information into an electronic medical records system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: map of UV-induced damage in yeast genome, comparative epigenomics uncovers plant lacking key DNA methyltransferase enzyme, and more.

Researchers kick off their second Queer in STEM survey to examine what can make STEM careers welcoming, Wired reports.

A startup company is offering a test to analyze soil samples from farms for pathogens.

Prosecutors seek to introduce evidence from low-template DNA analysis in a murder case in upstate New York, the New York Times reports.